Loading…
← CockpitCompetitor Analysis › RCUS Arcus Biosciences, Inc.Open in the cockpit ↗

Arcus Biosciences, Inc.RCUSCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops immuno-oncology combination therapies, partnered with Gilead, for lung and gastrointestinal cancers.

Momentum laggard 9
Mkt cap
$2.27B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$39.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.0%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$15.76
1D-3.8%
1W-16.2%
1M-33.6%
3M-46.6%
6M-33.6%
YTD-33.9%
1Y-21.2%
ATR %7.3%
Beta1.56
52w lowhigh50.3% off high

What Arcus Biosciences does

Develops immuno-oncology combination therapies, partnered with Gilead, for lung and gastrointestinal cancers.

Revenue comes from Gilead, which since a 2020 deal has paid up front, shares development costs and owes milestone payments as drugs advance, while no Arcus drug is yet sold. Gilead is also a major shareholder, tying the two companies' fortunes together.

Products and services

  • Domvanalimab (TIGIT antibody)
  • Zimberelimab (PD-1 antibody)
  • Etrumadenant (adenosine receptor)

Customers

  • Oncologists/cancer centers (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Immuno-oncology combination therapy

What could go right

  • Pivotal trial data readouts with Gilead
  • Combination therapy differentiation

What could go wrong

  • TIGIT-class clinical trial setbacks industry-wide
  • Dependence on Gilead partnership

Moat: narrow (IP / patents). Broad immuno-oncology combination pipeline backed by a major Gilead partnership, but unproven vs standard of care.

Headquarters: Hayward, California, US · Founded: 2015 · Employees: 601

Named competitors

Arcus Biosciences at a glance

Size Arcus Biosciences (RCUS) is a United States Health Care company (Biotechnology) with a market value of $2.27B, the 1698th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.76 on 18 Nov 2026.

Performance Over six months the shares fell 33.6%, against -4.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue fell 58.3% over the last twelve months (peer median +9.4%); the operating margin is -475.0% (peer median -15.4%).

Valuation It trades at 17.6× enterprise value to sales against a peer median of 9.4× (5th most expensive of 15).

Backlog Backlog (remaining performance obligations) was $256M at 31 Dec 2025, down 51% on a year earlier — 1.0 years of trailing revenue. Backlog detail →

Short interest Short interest is 9.2% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 95RCUS 66
Six months, rebased to 100: Arcus Biosciences against the median of its 20 peers (local-currency closes).

Arcus Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$100M$247M$258M$117M$112M
Revenue growth—-4%+121%+4%—
Gross profit$91.0M$237M$248M$101M$98.0M
EBITDA-$466M-$376M-$300M-$324M-$266M
Net income-$453M-$353M-$283M-$307M-$267M
Free cash flow-$466M-$484M-$176M-$330M$432M
Capital expenditure$1.00M$2.00M$6.00M$24.0M$6.00M
Total debt$116M$198M$159M$121M$120M

Quarterly statements and history in the cockpit →

Arcus Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%LKFTVIMIAN302440PHVS300255BEAMCLDXZEALPVLA300676ALMRXNCRIMNMMBXMRVIRCUS6-month return →1-month return →
Up and to the right = strong over both horizons. Arcus Biosciences is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×5,000×10,000×VIMIAN302440BEAMCLDXZEALALMR300142RCUSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Arcus Biosciences is the large dot.

Arcus Biosciences competitors and peer comparison

Head to head with its named competitors (RCUS vs GILD vs MRK vs BMY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Arcus Biosciences RCUS$2.27B-34%-58%-475%17.6×n/a
Gilead Sciences GILD$210B+30%+7%38%7.3×-2.4%
Merck & MRK$340B+23%+5%18%5.7×8.3%
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%

How Arcus Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Arcus Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureRCUSPeer medianRank in peer set
1-month return-33.6%-1.8%lowest of 21
6-month return-33.6%-4.8%2nd lowest of 20
Distance from 52-week high-50.3%-32.8%5th lowest of 21
Revenue growth (TTM)-58.3%+9.4%4th lowest of 17
Operating margin-475.0%-15.4%2nd lowest of 15
EV / Sales17.6×9.4×5th most expensive of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a

Arcus Biosciences backlog

Arcus Biosciences reported $256M of remaining performance obligations at 31 Dec 2025, down 51% from a year earlier and flat from the previous quarter. That is 1.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Arcus Biosciences's main competitors?
Named competitors: Gilead Sciences (GILD), BeiGene (private or unlisted), Merck (MRK), Bristol Myers Squibb (BMY). The cockpit's measured peer set (industry) also includes Lakefront Biotherapeutics (LKFT.AS), Vimian (VIMIAN.ST), SKBS (302440.KS), Pharvaris (PHVS), Hebei Changshan Biochemical Pharmaceutical (300255.SZ), Beam Therapeutics (BEAM).
Is Arcus Biosciences expensive compared with its peers?
On ev / sales it trades at 17.6× against a peer median of 9.4×, 5th most expensive of 15 in its peer set.
How has Arcus Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -33.6% against -4.8% for the median peer; over one year -21.2%.
What is Arcus Biosciences's backlog?
Arcus Biosciences's remaining performance obligations (contracted revenue not yet recognised) were $256M at 31 Dec 2025, -51% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.